Assembly Biosciences

112 articles with Assembly Biosciences

• Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

  5/12/2022

  Assembly Biosciences, Inc. reported financial results and recent highlights for the first quarter ended March 31, 2022.

• Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2022

  4/1/2022

  Assembly Biosciences, Inc. announced a grant of stock options to one new employee to purchase 19,000 shares of the Company’s common stock with an exercise price of $2.06 per share, the closing price of Assembly Bio’s common stock on April 1, 2022.

• Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022

  3/21/2022

  Assembly Biosciences, Inc. will host a webcast on Thursday, March 31, 2022 from 8:00 – 9:00 am PT/11:00 am – 12:00 pm ET to introduce its new research program focused on a novel, orally bioavailable small-molecule approach to inhibit entry of HBV and hepatitis delta virus (HDV).

• Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

  3/10/2022

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases, reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.

• Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

  2/9/2022

  Assembly Biosciences, Inc. announced that John McHutchison, AO, MD, chief executive officer and president, will participate in a virtual fireside chat during the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 p.m. ET.

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 07, 2022

  1/7/2022

  Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 7,000 shares of the Company’s common stock with an exercise price of $2.45 per share, the closing price of Assembly Bio’s common stock on January 3, 2022.

• Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

  1/6/2022

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases, announced that John McHutchison, AO, MD, chief executive officer and president, will present during the HC Wainwright Virtual BIOCONNECT Conference, January 10-13, 2022.

• Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones

  1/4/2022

  Assembly Biosciences, Inc. today outlined anticipated progress and milestones for its development pipeline in 2022.

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 03, 2021

  12/3/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 21,000 shares of the Company’s common stock with an exercise price of $2.24 per share, the closing price of Assembly Bio’s common stock on December 1, 2021.

• Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio

  11/12/2021

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported preclinical data from the company’s newly selected core inhibitor candidate, ABI-4334 (4334), and clinical results from the Phase 1a study of ABI-H3733 (3733) in healthy volunteers at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting™

• Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

  11/4/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, reported financial results and recent highlights for the third quarter ended September 30, 2021.

• Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting

  11/1/2021

  Assembly Biosciences, Inc. today announced that clinical and preclinical data from its HBV core inhibitor program will be featured in one oral and two poster presentations, including one late breaking, during the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ®

• Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

  10/19/2021

  Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection.

• Assembly Bio Announces October Conference Participation

  10/6/2021

  Assembly Biosciences, Inc. announced participation in the below upcoming conferences focused on HBV: The Science of HBV Cure Meeting 2021 ONLINE Presenter : William Delaney, PhD, Chief Scientific Officer Date/Time : Tuesday, October 12 at 7:30 a.m. ET

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021

  10/1/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to two new employees to purchase an aggregate of 16,000 shares of the Company’s common stock with an exercise price of $3.46 per share, the closing price of Assembly Bio’s common stock on October 1, 2021.

• 

  Biotech Company Takes a Hit After Axing HBV Therapy over Safety Concerns

  9/2/2021

  Shares of Assembly Biosciences have fallen more than 20% in premarket trading after the company discontinued the development of a hepatitis B therapeutic candidate.

• Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158

  9/1/2021

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced its decision to discontinue development of ABI-H2158 (2158) following the observation of elevated ALT levels consistent with drug-induced hepatotoxicity in an ongoing Phase 2 trial.

• Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

  8/18/2021

  Assembly Biosciences, Inc. today announced it has selected a fourth core inhibitor candidate, ABI-4334 (4334), that has been optimized for potency, to advance into clinical development.

• Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

  8/5/2021

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the second quarter ended June 30, 2021.

• Assembly Bio Announces Key Promotions to Leadership Team

  8/3/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer.